Table 21.1 (continued)

Sr.

no.

Substitution at R1

Substitution at R2

Substitution at R3

Comments

References

15.

Second-generation inhibitor. Better activity as compared to

gefitinib as well as lapatinib

Ju et al.

(2018)

16.

Promising EGFR inhibitory activity with non-specific DNA

damage

Lin et al.

(2017)

17.

First-generation inhibitor having better potency but lesser

activity as compared to gefitinib

Li et al.

(2015)

18.

First-generation inhibitor having poor inhibitory activity but

good anticancer activity

Zou et al.

(2019)

19.

First-generation inhibitor having lesser potency than lapatinib

but better anti-proliferative activity

Cheng et al.

(2019)

20.

First-generation inhibitor having remarkable anti-proliferative

activity

Liang et al.

(2020)

21.

First-generation dual inhibitor for EGFR/VEGFR-2. More

potency than vandetanib

Zhang et al.

(2017)

392

V. Panwar et al.